We are live on ! Find out more
BBLGW

Bone Biologics Corp Warrants
BBLGW

2 hedge funds and large institutions have $551K invested in Bone Biologics Corp Warrants in 2025 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more capital invested

Capital invested by funds: $358K → $551K (+$193K)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

33% less funds holding

Funds holding: 3 → 2 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$2.43K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$3.87K
2
Bank of America
Bank of America
North Carolina
-$800
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$548K -$3.87K -250 -0.7%
UBS Group
2
UBS Group
Switzerland
$3K +$2.43K +157 +110%
Bank of America
3
Bank of America
North Carolina
– -$800 -100 Closed

BBLGW Hedge Fund Activity: Q4 2025 in Review

2 of the 8,238 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics Corp Warrants (BBLGW) for Q4 2025, worth a combined $551K — up 54% from $358K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of BBLGW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $2.43K. The largest seller was Citadel Advisors, cutting an estimated $3.87K.

  • 2 institutional investors held Bone Biologics Corp Warrants (BBLGW) as of Q4 2025, down from 3 in Q3 2025.
  • Funds reported $551K of Bone Biologics Corp Warrants stock for Q4 2025, up 54% quarter-over-quarter.
  • 0 funds opened new Bone Biologics Corp Warrants positions in Q4 2025 and 1 closed out, a net change of -1 holder.
  • The largest Bone Biologics Corp Warrants buyer in Q4 2025 was UBS Group, an estimated $2.43K added.
  • The largest Bone Biologics Corp Warrants seller in Q4 2025 was Citadel Advisors, an estimated $3.87K sold.

Based on aggregated 13F filings for Q4 2025.